No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

被引:26
|
作者
Riggio, Oliviero [1 ,2 ]
Nardelli, Silvia [1 ]
Pasquale, Chiara [1 ]
Pentassuglio, Ilaria [1 ]
Gioia, Stefania [1 ]
Onori, Eugenia [1 ]
Frieri, Camilla [1 ]
Salvatori, Filippo Maria [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Clin Med, Ctr Diag & Treatment Portal Hypertens, Rome, Italy
[2] Sapienza Univ Roma, Dipartimento Med Clin, Ctr Riferimento Ipertens Portale, Gastroenterol 2, Viale Univ 37, I-00185 Rome, Italy
关键词
TIPS; Hepatic encephalopathy; Liver cirrhosis; Albumin; PARACENTESIS PLUS ALBUMIN; COVERED STENT GRAFTS; RISK-FACTORS; REFRACTORY ASCITES; VARICEAL HEMORRHAGE; RANDOMIZED-TRIAL; CIRRHOSIS; PLACEMENT; MORTALITY; VARIABLES;
D O I
10.1007/s11011-015-9713-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepatic encephalopathy (HE) is a major problem in patients submitted to TIPS. Previous studies identified low albumin as a factor associated to post-TIPS HE. In cirrhotics with diuretic-induced HE and hypovolemia, albumin infusion reduced plasma ammonia and improved HE. Our aim was to evaluate if the incidence of overt HE (grade II or more according to WH) and the modifications of venous blood ammonia and psychometric tests during the first month after TIPS can be prevented by albumin infusion. Twenty-three patients consecutively submitted to TIPS were enrolled and treated with 1 g/Kg BW of albumin for the first 2 days after TIPS followed by 0,5 g/Kg BW at day 4th and 7th and then once a week for 3 weeks. Forty-five patients included in a previous RCT (Riggio et al. 2010) followed with the same protocol and submitted to no pharmacological treatment for the prevention of HE, were used as historical controls. No differences in the incidence of overt HE were observed between the group of patients treated with albumin and historical controls during the first month (34 vs 31 %) or during the follow-up (39 vs 48 %). Two patients in the albumin group and three in historical controls needed the reduction of the stent diameter for persistent HE. Venous blood ammonia levels and psychometric tests were also similarly modified in the two groups. Survival was also similar. Albumin infusion has not a role in the prevention of post-TIPS HE.
引用
收藏
页码:1275 / 1281
页数:7
相关论文
共 50 条
  • [31] Transjugular intrahepatic portosystemic shunt
    Ochs, A
    DIGESTIVE DISEASES, 2005, 23 (01) : 56 - 64
  • [32] Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt
    Bai, Ming
    He, Chuang-Ye
    Qi, Xing-Shun
    Yin, Zhan-Xin
    Wang, Jian-Hong
    Guo, Wen-Gang
    Niu, Jing
    Xia, Jie-Lai
    Zhang, Zhuo-Li
    Larson, Andrew C.
    Wu, Kai-Chun
    Fan, Dai-Ming
    Han, Guo-Hong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (03) : 774 - 785
  • [33] Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy
    Luo, Shi-Hua
    Chu, Jian-Guo
    Huang, He
    Zhao, Guo-Rui
    Yao, Ke-Chun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (09) : 1088 - 1099
  • [34] Diabetes mellitus increases the risk of hepatic encephalopathy after a transjugular intrahepatic portosystemic shunt in cirrhotic patients
    Yin, Xiaochun
    Zhang, Feng
    Xiao, Jiangqiang
    Wang, Yi
    He, Qibin
    Zhu, Hao
    Leng, Xiafei
    Zou, Xiaoping
    Zhang, Ming
    Zhuge, Yuzheng
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (10) : 1264 - 1269
  • [35] Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision
    Michael W. Rowley
    Myunghan Choi
    Steve Chen
    Kevin Hirsch
    Anil B. Seetharam
    CardioVascular and Interventional Radiology, 2018, 41 : 1765 - 1772
  • [36] Transjugular intrahepatic portosystemic shunt - current status in 2011
    Angermayr, Bernhard
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2011, 74 (04) : 553 - 559
  • [37] Analysis of independent risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis combined with diabetes
    Chen, Huan
    Cai, Zihao
    Da, Binlin
    Wang, Chunxiang
    Yin, Qin
    Xiao, Jiangqiang
    Zhang, Ming
    Zhuge, Yuzheng
    Zhang, Feng
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 37 (02) : 214 - 218
  • [38] Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and post-transjugular intrahepatic portosystemic shunt complications in 2020
    Horhat, Adelina
    Bureau, Christophe
    Thabut, Dominique
    Rudler, Marika
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (02) : 203 - 208
  • [39] Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification
    Fonio, Paolo
    Discalzi, Andrea
    Calandri, Marco
    Breatta, Andrea Doriguzzi
    Bergamasco, Laura
    Martini, Silvia
    Ottobrelli, Antonio
    Righi, Dorico
    Gandini, Giovanni
    RADIOLOGIA MEDICA, 2017, 122 (09): : 713 - 721
  • [40] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang Yang
    Sirui Fu
    Bin Cao
    Kenan Hao
    Yong Li
    Jianwen Huang
    Wenfeng Shi
    Chongyang Duan
    Xiao Bai
    Kai Tang
    Shirui Yang
    Xiaofeng He
    Ligong Lu
    Hepatology International, 2021, 15 : 730 - 740